Trial Profile
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Capecitabine; Docetaxel; Eribulin; Exemestane; Fulvestrant; Gemcitabine; Letrozole; Paclitaxel; Tamoxifen; Taxanes; Trastuzumab emtansine; Vinorelbine
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms PATRICIA II; SOLTI-1303 PATRICIA II
- 06 Oct 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.
- 06 Oct 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2023.
- 06 Oct 2023 Status changed from recruiting to active, no longer recruiting.